Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578 with Nivolumab and Chemotherapy in HER2-Negative Gastric Cancer
NCT06256328Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ONO-4578 in gastric cancer (GC), sponsored by Ono Pharmaceutical. Started Jan 2024; status: active, not recruiting.
02
Drugs
ONO-4578
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06256328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256328.